Matches in SemOpenAlex for { <https://semopenalex.org/work/W2127644635> ?p ?o ?g. }
- W2127644635 abstract "Patients with large prostate volumes have been shown to have higher rates of genitourinary and gastrointestinal toxicities after conventional radiation therapy for prostate cancer. The efficacy and toxicity of stereotactic body radiation therapy (SBRT), which delivers fewer high-dose fractions of radiation treatment, is unknown for large prostate volume prostate cancer patients. We report our early experience using SBRT for localized prostate cancer in patients with large prostate volumes.57 patients with prostate volumes ≥50 cm(3) prior to treatment with SBRT for localized prostate carcinoma and with a minimum follow up of two years were included in this retrospective review of prospectively collected data. Treatment was delivered using Cyberknife (Accuray) with doses of 35-36.25 Gy in 5 fractions. Biochemical control was assessed using the Phoenix definition. Toxicities were scored using the CTCAE v.4. Quality of life was assessed using the American Urological Association (AUA) Symptom Score and the Expanded Prostate Cancer Index Composite (EPIC)-26.57 patients (23 low-, 25 intermediate- and 9 high-risk according to the D'Amico classification) at a median age of 69 years (range, 54-83 years) received SBRT with a median follow-up of 2.9 years. The median prostate size was 62.9 cm(3) (range 50-138.7 cm(3)). 33.3% of patients received ADT. The median pre-treatment prostate-specific antigen (PSA) was 6.5 ng/ml and decreased to a median PSA of 0.4 ng/ml by 2 years (p <0.0001). A mean baseline AUA symptom score of 7.5 significantly increased to 13 at 1 month (p = 0.001) and returned to baseline by 3 months (p = 0.21). 23% of patients experienced a late transient urinary symptom flare in the first two years following treatment. Mean baseline EPIC bowel scores of 95.8 decreased to 78.1 at 1 month (p <0.0001), but subsequently improved to 93.5 three months (p = 0.08). The 2-year actuarial incidence rates of GU and GI toxicity ≥ grade 2 were 49.1% and 1.8%, respectively. Two patients (3.5%) experienced grade 3 urinary toxicity, and no patient experienced grade 3 gastrointestinal toxicity.SBRT for clinically localized prostate cancer was well tolerated in men with large prostate volumes." @default.
- W2127644635 created "2016-06-24" @default.
- W2127644635 creator A5013566053 @default.
- W2127644635 creator A5037942654 @default.
- W2127644635 creator A5055224745 @default.
- W2127644635 creator A5056302482 @default.
- W2127644635 creator A5056324966 @default.
- W2127644635 creator A5056978586 @default.
- W2127644635 creator A5066696801 @default.
- W2127644635 creator A5071648735 @default.
- W2127644635 creator A5088627299 @default.
- W2127644635 date "2014-11-15" @default.
- W2127644635 modified "2023-10-14" @default.
- W2127644635 title "Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm3)" @default.
- W2127644635 cites W1516952155 @default.
- W2127644635 cites W154575524 @default.
- W2127644635 cites W1563830423 @default.
- W2127644635 cites W1932364922 @default.
- W2127644635 cites W1970337331 @default.
- W2127644635 cites W1977733462 @default.
- W2127644635 cites W1988003121 @default.
- W2127644635 cites W1989268854 @default.
- W2127644635 cites W1995770171 @default.
- W2127644635 cites W1996695354 @default.
- W2127644635 cites W1998994416 @default.
- W2127644635 cites W2002612178 @default.
- W2127644635 cites W2004831483 @default.
- W2127644635 cites W2008090769 @default.
- W2127644635 cites W2017090095 @default.
- W2127644635 cites W2022056595 @default.
- W2127644635 cites W2023980435 @default.
- W2127644635 cites W2025691442 @default.
- W2127644635 cites W2027570282 @default.
- W2127644635 cites W2044032707 @default.
- W2127644635 cites W2054899405 @default.
- W2127644635 cites W2066640264 @default.
- W2127644635 cites W2068430627 @default.
- W2127644635 cites W2069391245 @default.
- W2127644635 cites W2074378530 @default.
- W2127644635 cites W2076965963 @default.
- W2127644635 cites W2078121754 @default.
- W2127644635 cites W2083321519 @default.
- W2127644635 cites W2090968159 @default.
- W2127644635 cites W2093867637 @default.
- W2127644635 cites W2094442174 @default.
- W2127644635 cites W2095549404 @default.
- W2127644635 cites W2098733695 @default.
- W2127644635 cites W2101001966 @default.
- W2127644635 cites W2102643264 @default.
- W2127644635 cites W2108134400 @default.
- W2127644635 cites W2111097829 @default.
- W2127644635 cites W2114188582 @default.
- W2127644635 cites W2117792530 @default.
- W2127644635 cites W2124594281 @default.
- W2127644635 cites W2137282952 @default.
- W2127644635 cites W2137487758 @default.
- W2127644635 cites W2140307920 @default.
- W2127644635 cites W2145201478 @default.
- W2127644635 cites W2148117492 @default.
- W2127644635 cites W2152182740 @default.
- W2127644635 cites W2164748078 @default.
- W2127644635 cites W2165244734 @default.
- W2127644635 cites W2171127338 @default.
- W2127644635 cites W2172038823 @default.
- W2127644635 cites W2172151487 @default.
- W2127644635 cites W2993539218 @default.
- W2127644635 cites W4245157701 @default.
- W2127644635 doi "https://doi.org/10.1186/s13014-014-0241-3" @default.
- W2127644635 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4239322" @default.
- W2127644635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25398516" @default.
- W2127644635 hasPublicationYear "2014" @default.
- W2127644635 type Work @default.
- W2127644635 sameAs 2127644635 @default.
- W2127644635 citedByCount "33" @default.
- W2127644635 countsByYear W21276446352015 @default.
- W2127644635 countsByYear W21276446352016 @default.
- W2127644635 countsByYear W21276446352017 @default.
- W2127644635 countsByYear W21276446352018 @default.
- W2127644635 countsByYear W21276446352019 @default.
- W2127644635 countsByYear W21276446352020 @default.
- W2127644635 countsByYear W21276446352021 @default.
- W2127644635 countsByYear W21276446352022 @default.
- W2127644635 countsByYear W21276446352023 @default.
- W2127644635 crossrefType "journal-article" @default.
- W2127644635 hasAuthorship W2127644635A5013566053 @default.
- W2127644635 hasAuthorship W2127644635A5037942654 @default.
- W2127644635 hasAuthorship W2127644635A5055224745 @default.
- W2127644635 hasAuthorship W2127644635A5056302482 @default.
- W2127644635 hasAuthorship W2127644635A5056324966 @default.
- W2127644635 hasAuthorship W2127644635A5056978586 @default.
- W2127644635 hasAuthorship W2127644635A5066696801 @default.
- W2127644635 hasAuthorship W2127644635A5071648735 @default.
- W2127644635 hasAuthorship W2127644635A5088627299 @default.
- W2127644635 hasBestOaLocation W21276446351 @default.
- W2127644635 hasConcept C121608353 @default.
- W2127644635 hasConcept C126322002 @default.
- W2127644635 hasConcept C126894567 @default.
- W2127644635 hasConcept C133507102 @default.
- W2127644635 hasConcept C2776235491 @default.
- W2127644635 hasConcept C2776651944 @default.